Episode 200: Gilead's growing pains, Covid's origins, & Theranos as prestige TV
The Readout Loud
00:00
Gilead Announces Results From Trial Using Trudelvi in Breast Cancer Patients
Gilead sciences acquired the drug maker immunimetics for 21 billion dollars. The centrepiece of that very large deal was a breast cancer drug called todelvi, which gilead believed could be a foundational product in its oncology business. But two years later, Gilead's plan for trudelvi appears to be in some trouble. Earlier this week, the company announced results from a closely watched clinical trial involvingtrudelvi in women with the most common form of breast cancer.
Transcript
Play full episode
